Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Summary

This phase I/II trial is studying the side effects and best dose of oblimersen and to see how well it works in treating patients with relapsed or refractory Waldenstrom's macroglobulinemia. Biological therapies such as oblimersen may interfere with the growth of the cancer cells and slow or stop the growth of Waldenstrom's macroglobulinemia.

Timeline

Start

2003-05

Primary completion

2007-06

Completion

—

Drugs

Indications